Australia markets closed

0G99.IL,0P0000BLMJ,0 (0G99.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
0.00020.0000 (0.00%)
As of 09:00PM BST. Market open.
Full screen
Previous close0.0002
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • GlobeNewswire

    Oxurion Share Consolidation

    Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares. This share consolidation is a strategic step to increase th

  • GlobeNewswire

    Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

    Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting. All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website Oxurion/

  • GlobeNewswire

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM